Esophageal Squamous Cell Carcinoma Market Research Report Information By Diagnosis and Treatment (Diagnosis and Treatment) by End User (Hospital, Specialty Centers and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2032

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 INCREASING PREVALENCE OF ACHALASIA

4.2.2 INCREASED RESEARCH ACTIVITIES AND PRODUCT APPROVALS

4.2.3 RISING PUBLIC AWARENESS

4.3 RESTRAINTS

4.3.1 HIGH COST OF TREATMENT

4.3.2 SIDE EFFECTS OF ESOPHAGEAL CANCER DRUGS

4.4 OPPORTUNITIES

4.4.1 RISE IN CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D & DESIGNING

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER'S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

5.3.1 IMPACT ON DEMAND

5.3.2 IMPACT ON SUPPLY CHAIN

5.3.3 IMPACT ON MARKET PLAYERS)

5.4 TOTAL NUMBER OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS, BY REGION

5.5 ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENT FORECAST, (2018-2024)

5.6 STANDARD OF CARE (SOC) FOR THE TREATMENT

5.6.1 STANDARD OF CARE (SOC) FOR SURGERY:

5.6.2 STANDARD OF CARE (SOC) FOR CHEMOTHERAPY:

5.6.3 STANDARD OF CARE (SOC) FOR RADIOTHERAPY:

5.6.4 STANDARD OF CARE (SOC) FOR THE IMMUNOTHERAPY:

5.6.5 STANDARD OF CARE (SOC) FOR OTHER TREATMENTS

6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY DIAGNOSIS & TREATMENT

6.1 OVERVIEW

6.2 DIAGNOSIS

6.2.1 ENDOSCOPY

6.2.2 CT SCAN

6.2.3 ESOPHAGRAM

6.2.4 POSITRON EMISSION TOMOGRAPHY (PET)

6.2.5 OTHERS

6.3 TREATMENT

6.3.1 SURGERY

6.3.2 CHEMOTHERAPY

6.3.3 RADIOTHERAPY

6.3.4 IMMUNOTHERAPY

6.3.5 OTHERS

7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET BY END USER

7.1 OVERVIEW

7.1.1 HOSPITALS

7.1.2 SPECIALTY CENTERS

7.1.3 OTHERS

8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION

8.1 GLOBAL

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 CHINA

8.4.2 INDIA

8.4.3 JAPAN

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

9.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

9.5 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.5.1 PRODUCT LAUNCHES/PRODUCT APPROVALS

9.6 FINANCIAL MATRIX

9.6.1 SALES (USD MILLION), 2021

9.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 F. HOFFMANN-LA ROCHE LTD

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 ASTRAZENECA

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 SWOT ANALYSIS

10.2.6 KEY STRATEGIES

10.3 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

10.3.1 COMPANY OVERVIEWS

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 SEAGEN INC.

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 KEY STRATEGIES

10.5 ELI LILLY AND COMPANY

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 SWOT ANALYSIS

10.5.6 KEY STRATEGIES

10.6 GLAXOSMITHKLINE PLC

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 NOVARTIS AG

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 KEY STRATEGIES

10.9 JACOBIO PHARMACEUTICALS GROUP CO., LTD.

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 4 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY REGION, 2018–2030 (USD MILLION)

TABLE 5 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ENDOSCOPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CT SCAN, BY REGION, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR ESOPHAGRAM, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR POSITRON EMISSION TOMOGRAPHY (PET), BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR CHEMOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR RADIOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR IMMUNOTHERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 19 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR HOSPITALS, BY REGION, 2018–2030 (USD MILLION)

TABLE 20 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR SPECIALTY CENTERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 21 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 22 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 23 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 24 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 26 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 27 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 28 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 29 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 30 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 31 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 32 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 33 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 34 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 35 US: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 36 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 37 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 39 CANADA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 40 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 41 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 42 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 43 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 44 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 45 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 47 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 48 GERMANY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 49 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 50 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 51 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 52 UK: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 53 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 54 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 55 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 56 FRANCE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 57 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 58 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 59 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 60 ITALY: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 61 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 64 SPAIN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 65 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 66 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018–2030 (USD MILLION)

TABLE 67 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT, BY TYPE, 2018-2030

TABLE 68 REST OF EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 74 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 75 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 76 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 77 CHINA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 78 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 79 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 80 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 81 INDIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 82 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 83 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 84 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 85 JAPAN: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 86 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 87 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 88 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 89 AUSTRALIA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 90 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 91 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 92 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 93 SOUTH KOREA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 94 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 95 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 96 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 97 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 98 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY COUNTRY, 2018-2030 (USD MILLION)

TABLE 99 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 100 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 101 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 102 REST OF ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 103 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 104 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 105 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 106 MIDDLE EAST: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 107 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 108 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 109 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 110 AFRICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 111 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2018–2030 (USD MILLION)

TABLE 112 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR DIAGNOSIS, BY TYPE, 2018-2030 (USD MILLION)

TABLE 113 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, FOR TREATMENT BY TYPE, 2018–2030 (USD MILLION)

TABLE 114 LATIN AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2018–2030 (USD MILLION)

TABLE 115 MAJOR PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

TABLE 116 MOST ACTIVE PLAYER IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

TABLE 117 PRODUCT LAUNCHES/PRODUCT APPROVALS

TABLE 118 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED

TABLE 119 ASTRAZENECA: PRODUCTS OFFERED

TABLE 120 ASTRAZENECA: KEY DEVELOPMENTS

TABLE 121 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED

TABLE 122 CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.: KEY DEVELOPMENTS

TABLE 123 SEAGEN INC: PRODUCTS OFFERED

TABLE 124 SEAGEN INC.: KEY DEVELOPMENTS

TABLE 125 ELI LILLY AND COMPANY: PRODUCTS OFFERED

TABLE 126 ELI LILLY AND COMPANY: KEY DEVELOPMENTS

TABLE 127 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED

TABLE 128 NOVARTIS AG: PRODUCTS OFFERED

TABLE 129 BEIJING SHENZHOU CELL BIOTECHNOLOGY GROUP CO., LTD.: PRODUCTS OFFERED

TABLE 130 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINT IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

FIGURE 9 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; GENDER SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 10 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS & TREATMENT, 2021 & 2030 (USD MILLION)

FIGURE 11 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY DIAGNOSIS, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)

FIGURE 13 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET; END USER SEGMENT ATTRACTIVENESS, (USD MILLION)

FIGURE 14 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, BY END USER, 2021 & 2030 (USD MILLION)

FIGURE 15 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (% SHARE)

FIGURE 16 GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY REGION, 2021 (USD MILLION)

FIGURE 17 NORTH AMERICA MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)

FIGURE 18 NORTH AMERICA: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)

FIGURE 19 EUROPE MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)

FIGURE 20 EUROPE: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)

FIGURE 21 ASIA-PACIFIC: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)

FIGURE 22 ASIA-PACIFIC: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE, BY COUNTRY, 2021 (% SHARE)

FIGURE 23 REST OF THE WORLD: MARKET ANALYSIS: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET, 2018-2030 (USD MILLION)

FIGURE 24 REST OF THE WORLD: ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET SHARE (%), BY COUNTRY, 2021

FIGURE 25 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 26 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MARKET

FIGURE 27 SALES, 2021

FIGURE 28 RESEARCH & DEVELOPMENT EXPENDITURE, 2021

FIGURE 29 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS

FIGURE 31 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 ASTRAZENECA: SWOT ANALYSIS

FIGURE 33 SEAGEN INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 ELI LILLY AND COMPANY: SWOT ANALYSIS

FIGURE 36 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 38 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 NOVARTIS AG: SWOT ANALYSIS

FIGURE 40 JACOBIO PHARMACEUTICALS GROUP CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT